RNS Number : 3983D
Proximagen Group PLC
15 May 2012
15 May 2012
PROXIMAGEN GROUP PLC
("Proximagen" or "the Company")
Result of Annual General Meeting
London, UK, 15 May 2012 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system and inflammatory diseases, announces that at its Annual General Meeting which was held earlier today, all resolutions put to shareholders were duly passed.
Proximagen Group plc Tel: +44 (0)20 7400 7700
James Hunter, Finance Director
Singer Capital Markets (Nominated Tel: +44 (0)20 3205 7500
Shaun Dobson/Claes Spang
M:Communications (Media enquiries) Tel: +44 (0)20 7920 2330
Mary-Jane Elliott / Sarah Macleod email@example.com
/ Hollie Vile
Proximagen Group plc (AIM:PRX) is a European biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.
The Company is developing potential new best-in-class therapeutics in its core disease areas including epilepsy, Parkinson's disease, and Alzheimer's disease, as well as in other areas such as inflammation, oncology and neuropathic pain.
Proximagen has a number of existing partnerships with pharmaceutical companies including GlaxoSmithKline, Upsher-Smith and Lundbeck, and is developing a broad pipeline of drug candidate programmes, with four programmes in clinical development and more than ten earlier stage assets being progressed.
Proximagen's strategy is to advance its pipeline with its partners and to acquire innovative drug candidates that complement its pipeline, with the objective of scaling up its risk-mitigated operating model and generating sustainable profits.
For more information, please visit www.proximagen.com.
This information is provided by RNS
The company news service from the London Stock Exchange